Related Experiment Video
Updated: Jan 3, 2026

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
Published on: May 9, 2019
Loss of Lgals3 Protects Against Gonadectomy-Induced Cortical Bone Loss in Mice
Kevin A Maupin1, Daniel Dick1, Johan Lee1
1Program for Skeletal Disease and Tumor Microenvironment and Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, MI, USA.
Abstract:
Sex hormone deprivation commonly occurs following menopause in women or after androgen-depletion during prostate cancer therapy in men, resulting in rapid bone turnover and loss of bone mass. There is a need to identify novel therapies to improve bone mass in these conditions. Previously, we identified age- and sex-dependent effects on bone mass in mice with deletion of the gene encoding the β-galactoside binding lectin, galectin-3 (Lgals3-KO). Due to the influence of sex on the phenotype, we tested the role of sex hormones, estrogen (β-estradiol; E2), and androgen (5α-dihydroxytestosterone; DHT) in Lgals3-KO mice. To address this, we subjected male and female wild-type and Lgals3-KO mice to gonadectomy ± E2 or DHT rescue and compared differential responses in bone mass and bone formation. Following gonadectomy, male and female Lgals3-KO mice had greater cortical bone expansion (increased total area; T.Ar) and reduced loss of bone area (B.Ar). While T.Ar and B.Ar were increased in response to DHT in wild-type mice, DHT did not alter these parameters in Lgals3-KO mice. E2 rescue more strongly increased B.Ar in Lgals3-KO compared to wild-type female mice due to a failure of E2 to repress the increase in T.Ar following gonadectomy. Lgals3-KO mice had more osteoblasts relative to bone surface when compared to wild-type animals in sham, gonadectomy, and E2 rescue groups. DHT suppressed this increase. This study revealed a mechanism for the sex-dependency of the Lgals3-KO aging bone phenotype and supports targeting galectin-3 to protect against bone loss associated with decreased sex hormone production.
Insights
Targeting galectin-3 (Lgals3-KO) may protect against bone loss after sex hormone loss. Lgals3-KO mice show altered bone responses to estrogen and androgens, suggesting a therapeutic target.
Area of Science:
- Endocrinology
- Bone Biology
- Molecular Biology
Background:
- Sex hormone deprivation, common after menopause or prostate cancer therapy, causes bone loss.
- Galectin-3 (Lgals3) deletion in mice (Lgals3-KO) shows sex-dependent effects on bone mass.
- Novel therapies are needed to counteract bone loss due to diminished sex hormones.
Purpose of the Study:
- To investigate the role of estrogen (E2) and androgen (DHT) in the bone phenotype of Lgals3-KO mice.
- To understand the sex-dependent mechanisms underlying bone loss in Lgals3-KO mice.
Main Methods:
- Male and female wild-type and Lgals3-KO mice underwent gonadectomy with or without E2 or DHT hormone rescue.
- Bone mass, bone area (B.Ar), total area (T.Ar), and osteoblast number were compared between groups.
Main Results:
- Lgals3-KO mice exhibited greater cortical bone expansion and reduced bone loss after gonadectomy.
- DHT increased bone parameters in wild-type but not Lgals3-KO mice.
- Estrogen (E2) rescue more effectively increased bone area in Lgals3-KO females, but failed to repress total area expansion.
Conclusions:
- Galectin-3 influences the sex-dependent bone response to sex hormone deprivation.
- Targeting galectin-3 may offer a novel therapeutic strategy for preventing bone loss associated with low sex hormones.

